Big Pharmas Back $300m Neglected Disease Fund
Cash For Projects 'Wall Street and Silicon Valley Pay Little Attention To'
Adjuvant Capital believes its fund will ultimately lead to greater access to medical advances in low-income countries while making a healthy return for its high-profile investors.
You may also be interested in...
Novartis and Takeda’s R&D efforts saw an impact from the COVID-19 pandemic, but both Lutz Hegemann and Andrew Plump believe that when the next pandemic hits, the industry and regulators will be better prepared for it.
The Swiss major envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once directly to the patient without the need to modify cells in a lab.
In the absence of head-to-head data, the results from a "matching-adjusted indirect comparison" suggest favorable efficacy of the German group's treatment for solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion when compared with competitor Rozlytrek from Roche.